2015-04-16 Call Buyers See 8%+ Upside In Abbott Labs By August (ABT)
Call Buyers See 8%+ Upside In Abbott Labs By August (ABT)
Notes: Back in February, Abbott Laboratories sold part of their generic drug business to Mylan NV (MYL) for $5.3B in February. With earnings projected to decline 6% this year, I would look for more deals to come from $70B pharmaceutical company (whether it is via shedding more assets or acquiring smaller competition that are accretive to earnings). They had about $4.4B in cash and short-term investments to start off of the year (not including the recent sale). ABT shares trade at a P/E ratio of 19.51x (2016 estimates), price to sales ratio of 3.48x, and a price to book ratio of 3.27x. Q1 earnings are due out on April 22nd (moved higher after earnings on 5 out of the last 7 reports).
Abbott Laboratories (ABT) Options Trade Idea
Buy the (ABT) May $47/$50 bull call spread for a $0.90 debit or better
(Buy the May $47 call and sell the May $50 call, all in one trade)
Stop loss- None
1st upside target- $1.80
2nd upside target- $2.70
ORM Market Commentary (5-10 trades/analysis of stocks, ETFs, and indices per day like in the Free Trade of the Day above) is included in my ORM Equity/Option Trader Subscription Service for $9.99 per month (available now!).
1 On 1 Options Mentoring: Learn more about my 1 on 1 equity/options mentoring courses that help can you improve your trading odds and risk management skills (courses start as low as $55!).
